Dimerix signs up first patient for 'highly significant' paediatric clinical trial
Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3 clinical trial in a major next step for the research.The trial will investigate the efficacy of DMX-200 in children aged 12 to 17 with focal seg...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.